Related Experiment Video
Updated: Aug 4, 2026
07:19
Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Naproxen in osteoarthrosis. Double-blind crossover trial
Annals of the Rheumatic Diseases
|February 1, 1978
Summary
Naproxen effectively treats hip and knee osteoarthrosis, outperforming placebo in symptom relief and patient preference. This well-tolerated medication demonstrated significant efficacy in clinical trials.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Osteoarthrosis of the hip and knee is a prevalent degenerative joint disease.
- Effective and well-tolerated treatment options are crucial for managing osteoarthrosis symptoms.
Purpose of the Study:
- To evaluate the efficacy and tolerability of naproxen compared to placebo in patients with hip and knee osteoarthrosis.
Main Methods:
- A double-blind, crossover trial design was employed.
- Patients received naproxen (750 mg/day) or placebo for two 4-week periods, alternating treatments.
- Objective and subjective efficacy measures, patient symptom checklists, and physician/patient preferences were assessed.
Main Results:
- Naproxen demonstrated statistically significant superiority over placebo across 8 out of 9 efficacy measures (P = 0.0001 to 0.0004).
- Patient-reported osteoarthrotic symptoms were significantly reduced with naproxen therapy.
- Both physicians and patients expressed a significant preference for naproxen over placebo.
Conclusions:
- Naproxen is an effective and well-tolerated treatment for osteoarthrosis of the hip and knee.
- The drug offers significant symptomatic relief and is preferred by patients and physicians.
- Adverse event incidence was low and comparable between naproxen and placebo groups.
